Delivra Health BrandsDHBUF Piotroski F-Score is 2 as of Jul. 01, 2026, which is 50% below its 10-year median of 4.00. The stock has 3 warning signs investors should review. Among 979 Drug Manufacturers companies, Delivra Health Brands ranks worse than 91.32% on this metric.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Delivra Health Brands has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Delivra Health Brands's Piotroski F-Score or its related term are showing as below:
DHBUF'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 4 Max: 7
Current: 2
During the past 13 years, the highest Piotroski F-Score of Delivra Health Brands was 7. The lowest was 2. And the median was 4.
Delivra Health Brands (OTCPK:DHBUF) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Delivra Health Brands Piotroski F-Score Related Terms
Delivra Health Brands Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Delivra Health Brands's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Delivra Health Brands's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Delivra Health Brands Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Delivra Health Brands's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Delivra Health Brands's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Delivra Health Brands's current Net Income (TTM) was -0.73.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Delivra Health Brands's current Cash Flow from Operations (TTM) was -0.23.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Delivra Health Brands's return on assets of this year was -0.12222778. Delivra Health Brands's return on assets of last year was -0.00959302.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Delivra Health Brands's gearing of this year was 0.24004703. Delivra Health Brands's gearing of last year was 0.20686145.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Delivra Health Brands's current ratio of this year was 3.28879037. Delivra Health Brands's current ratio of last year was 3.43400713.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Delivra Health Brands's number of shares in issue this year was 31.262. Delivra Health Brands's number of shares in issue last year was 31.262.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Delivra Health Brands's gross margin of this year was 0.45543465. Delivra Health Brands's gross margin of last year was 0.4983962.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Delivra Health Brands's asset turnover of this year was 1.36384859. Delivra Health Brands's asset turnover of last year was 1.31409884.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
0
+
0
+
1
+
0
+
1
=
3
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Delivra Health Brands has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
Delivra Health Brands (DHBUF) has a Piotroski F-Score of 2 as of Jul. 01, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Delivra Health Brands and its competitors. This is 50% below median its historical median of 4.00. Over the past decade, Delivra Health Brands' Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Delivra Health Brands ranks #894 out of 979 companies in the Drug Manufacturers industry, placing it in the top 91.3%.
Is Delivra Health Brands' Piotroski F-Score too high?
Delivra Health Brands' current Piotroski F-Score of 2 is 50% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Delivra Health Brands' value of 2 is 60% below this industry median. Based on the distribution chart, Delivra Health Brands ranks #894 out of 979 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Delivra Health Brands' Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Delivra Health Brands ranks #894 out of 979 companies for Piotroski F-Score. This places Delivra Health Brands in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Delivra Health Brands' value of 2 is 60% below this benchmark. Historically, Delivra Health Brands' own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Delivra Health Brands has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Delivra Health Brands's current Piotroski F-Score of 2 is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Delivra Health Brands and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Delivra Health Brands's current Piotroski F-Score is 2, which is 50% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delivra Health Brands stock overvalued right now?
Based on GuruFocus' analysis, Delivra Health Brands (DHBUF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.19, compared to a current price of $0.07 — trading 62.7% below its estimated fair value. The current Piotroski F-Score is 2, which is 50% below median its 10-year median of 4.00 and 60% below the Drug Manufacturers industry median of 5.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Delivra Health Brands (DHBUF), the current Piotroski F-Score is 2 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Delivra Health Brands Inc helping people take control of health with alternative wellness solutions. Its portfolio features brands like Dream Water and LivRelief that deliver relief from common, everyday issues like chronic pain, anxiety, and sleeplessness. The principal activities of the company are to provide lifestyle and health and wellness products to consumers and patients in regulated markets. The company geographically operates in Canada and United States, out of which it generates maximum revenue from Unites States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHBUF has been successfully added to your 